A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Clinical trial NCT04494256 · TERMINATED

Trial details

NCT number: NCT04494256
Sponsor: Biogen
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Amyotrophic Lateral Sclerosis

Start date: 2020-09-28
Primary completion: 2024-08-13
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.